These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. The influence of Type A behavior pattern on the response to the panicogenic agent CCK-4. Le Mellédo JM; Arthur H; Dalton J; Woo C; Lipton N; Bellavance F; Koszycki D; Boulenger JP; Bradwejn J J Psychosom Res; 2001 Sep; 51(3):513-20. PubMed ID: 11602221 [TBL] [Abstract][Full Text] [Related]
30. Comparison of the effects of cholecystokinin-tetrapeptide and carbon dioxide in health volunteers. Koszycki D; Bradwejn J; Bourin M Eur Neuropsychopharmacol; 1991 May; 1(2):137-41. PubMed ID: 1821703 [TBL] [Abstract][Full Text] [Related]
31. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. Bradwejn J; Koszycki D; Paradis M; Reece P; Hinton J; Sedman A Biol Psychiatry; 1995 Dec; 38(11):742-6. PubMed ID: 8580227 [TBL] [Abstract][Full Text] [Related]
32. Thyrotropin-releasing hormone: a potential comparator for the panicogenic effects of pentagastrin and CCK? Coupland N; Malizia A; Bailey J; Nutt D Biol Psychiatry; 1996 Mar; 39(6):465-6. PubMed ID: 8679797 [No Abstract] [Full Text] [Related]
33. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Bradwejn J; Koszycki D; Couëtoux du Tertre A; van Megen H; den Boer J; Westenberg H Arch Gen Psychiatry; 1994 Jun; 51(6):486-93. PubMed ID: 8192551 [TBL] [Abstract][Full Text] [Related]
34. Effects of CCK-4 infusion on the acoustic eye-blink startle and psychophysiological measures in healthy volunteers. Shlik J; Zhou Y; Koszycki D; Vaccarino FJ; Bradwejn J J Psychopharmacol; 1999 Dec; 13(4):385-90. PubMed ID: 10667615 [TBL] [Abstract][Full Text] [Related]
35. Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers. Bradwejn J; Koszycki D; Couëtoux du Tertre A; Paradis M; Bourin M Psychopharmacology (Berl); 1994 Mar; 114(2):257-61. PubMed ID: 7838917 [TBL] [Abstract][Full Text] [Related]
36. Effects of CCK-tetrapeptide in patients with social phobia and obsessive-compulsive disorder. Katzman MA; Koszycki D; Bradwejn J Depress Anxiety; 2004; 20(2):51-8. PubMed ID: 15390214 [TBL] [Abstract][Full Text] [Related]
37. Acute and chronic role of 5-HT3 neuronal system on behavioral and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans. Dépôt M; Caillé G; Mukherjee J; Katzman MA; Cadieux A; Bradwejn J Neuropsychopharmacology; 1999 Feb; 20(2):177-87. PubMed ID: 9885797 [TBL] [Abstract][Full Text] [Related]
38. The 5-HTTLPR genotype modulates heart rate variability and its adjustment by pharmacological panic challenge in healthy men. Agorastos A; Kellner M; Stiedl O; Muhtz C; Becktepe JS; Wiedemann K; Demiralay C J Psychiatr Res; 2014 Mar; 50():51-8. PubMed ID: 24342768 [TBL] [Abstract][Full Text] [Related]
39. Metabotropic glutamate2/3 receptor agonism facilitates autonomic recovery after pharmacological panic challenge in healthy humans. Agorastos A; Demiralay C; Stiedl O; Muhtz C; Wiedemann K; Kellner M Int Clin Psychopharmacol; 2016 May; 31(3):176-8. PubMed ID: 26752621 [TBL] [Abstract][Full Text] [Related]
40. Effects of repetitive transcranial magnetic stimulation (rTMS) on panic attacks induced by cholecystokinin-tetrapeptide (CCK-4). Zwanzger P; Eser D; Völkel N; Baghai TC; Möller HJ; Rupprecht R; Padberg F Int J Neuropsychopharmacol; 2007 Apr; 10(2):285-9. PubMed ID: 16817979 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]